Pharmacotherapies for Obesity: Past, Current, and Future Therapies
Past therapies for the treatment of obesity have typically involved pharmacological agents usually in combination with a calorie-controlled diet. This paper reviews the efficacy and safety of pharmacotherapies for obesity focusing on drugs approved for long-term therapy (orlistat), drugs approved f...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Journal of Obesity |
| Online Access: | http://dx.doi.org/10.1155/2011/179674 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551310584446976 |
|---|---|
| author | Lisa L. Ioannides-Demos Loretta Piccenna John J. McNeil |
| author_facet | Lisa L. Ioannides-Demos Loretta Piccenna John J. McNeil |
| author_sort | Lisa L. Ioannides-Demos |
| collection | DOAJ |
| description | Past therapies for the treatment of obesity have typically involved pharmacological agents usually in combination with a calorie-controlled diet. This paper reviews the efficacy and safety of pharmacotherapies for obesity focusing on drugs approved for long-term therapy (orlistat), drugs approved for short-term use (amfepramone [diethylpropion], phentermine), recently withdrawn therapies (rimonabant, sibutamine) and drugs evaluated in Phase III studies (taranabant, pramlintide, lorcaserin and tesofensine and combination therapies of topiramate plus phentermine, bupropion plus naltrexone, and bupropion plus zonisamide). No current pharmacotherapy possesses the efficacy needed to produce substantial weight loss in morbidly obese patients. Meta-analyses support a significant though modest loss in bodyweight with a mean weight difference of 4.7 kg (95% CI 4.1 to 5.3 kg) for rimonabant, 4.2 kg (95% CI 3.6 to 4.8 kg) for sibutramine and 2.9 kg (95% CI 2.5 to 3.2 kg) for orlistat compared to placebo at ≥12 months. Of the Phase III pharmacotherapies, lorcaserin, taranabant, topiramate and bupropion with naltrexone have demonstrated significant weight loss compared to placebo at ≥12 months. Some pharmacotherapies have also demonstrated clinical benefits. Further studies are required in some populations such as younger and older people whilst the long term safety continues to be a major consideration and has led to the withdrawal of several drugs. |
| format | Article |
| id | doaj-art-3d1b5e666b4b46a1bdcd59fc8cdb2ffd |
| institution | Kabale University |
| issn | 2090-0708 2090-0716 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Obesity |
| spelling | doaj-art-3d1b5e666b4b46a1bdcd59fc8cdb2ffd2025-02-03T06:01:43ZengWileyJournal of Obesity2090-07082090-07162011-01-01201110.1155/2011/179674179674Pharmacotherapies for Obesity: Past, Current, and Future TherapiesLisa L. Ioannides-Demos0Loretta Piccenna1John J. McNeil2Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Alfred Centre, Commercial Road, Melbourne, VIC 3004, AustraliaDepartment of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Alfred Centre, Commercial Road, Melbourne, VIC 3004, AustraliaDepartment of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Alfred Centre, Commercial Road, Melbourne, VIC 3004, AustraliaPast therapies for the treatment of obesity have typically involved pharmacological agents usually in combination with a calorie-controlled diet. This paper reviews the efficacy and safety of pharmacotherapies for obesity focusing on drugs approved for long-term therapy (orlistat), drugs approved for short-term use (amfepramone [diethylpropion], phentermine), recently withdrawn therapies (rimonabant, sibutamine) and drugs evaluated in Phase III studies (taranabant, pramlintide, lorcaserin and tesofensine and combination therapies of topiramate plus phentermine, bupropion plus naltrexone, and bupropion plus zonisamide). No current pharmacotherapy possesses the efficacy needed to produce substantial weight loss in morbidly obese patients. Meta-analyses support a significant though modest loss in bodyweight with a mean weight difference of 4.7 kg (95% CI 4.1 to 5.3 kg) for rimonabant, 4.2 kg (95% CI 3.6 to 4.8 kg) for sibutramine and 2.9 kg (95% CI 2.5 to 3.2 kg) for orlistat compared to placebo at ≥12 months. Of the Phase III pharmacotherapies, lorcaserin, taranabant, topiramate and bupropion with naltrexone have demonstrated significant weight loss compared to placebo at ≥12 months. Some pharmacotherapies have also demonstrated clinical benefits. Further studies are required in some populations such as younger and older people whilst the long term safety continues to be a major consideration and has led to the withdrawal of several drugs.http://dx.doi.org/10.1155/2011/179674 |
| spellingShingle | Lisa L. Ioannides-Demos Loretta Piccenna John J. McNeil Pharmacotherapies for Obesity: Past, Current, and Future Therapies Journal of Obesity |
| title | Pharmacotherapies for Obesity: Past, Current, and Future Therapies |
| title_full | Pharmacotherapies for Obesity: Past, Current, and Future Therapies |
| title_fullStr | Pharmacotherapies for Obesity: Past, Current, and Future Therapies |
| title_full_unstemmed | Pharmacotherapies for Obesity: Past, Current, and Future Therapies |
| title_short | Pharmacotherapies for Obesity: Past, Current, and Future Therapies |
| title_sort | pharmacotherapies for obesity past current and future therapies |
| url | http://dx.doi.org/10.1155/2011/179674 |
| work_keys_str_mv | AT lisalioannidesdemos pharmacotherapiesforobesitypastcurrentandfuturetherapies AT lorettapiccenna pharmacotherapiesforobesitypastcurrentandfuturetherapies AT johnjmcneil pharmacotherapiesforobesitypastcurrentandfuturetherapies |